Drugs / igrelimogene litadenorepvec
igrelimogene litadenorepvec
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06961786 | Jun 2025 → Nov 2026 expected | metastatic melanoma | TILT Biotherapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06125197 | Jul 2024 → Jan 2026 overdue | lung cancer | TILT Biotherapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05222932 | Mar 2023 → Dec 2026 expected | head and neck squamous cell carcinoma, melanoma | TILT Biotherapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04695327 | Jan 2021 → Sep 2025 | cancer | TILT Biotherapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04217473 | Feb 2020 → Dec 2023 | metastatic melanoma | TILT Biotherapeutics Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05271318 | May 2022 → Mar 2027 expected | chemotherapy-induced toxicity, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | TILT Biotherapeutics Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | igrelimogene litadenorepvec | “The oncolytic adenovirus TILT-123 (Ad5/3-E2F-d24-hTNFA-IRES-hIL2, igrelimogene litadenorepvec) has demonstrated favorable safety profiles in phase 1 clinical trials in patients...” PMID 41566775 ↗ Jan 2026 |
| Known as | Ad5/3-E2F-d24-hTNFA-IRES-hIL2 | “The oncolytic adenovirus TILT-123 (Ad5/3-E2F-d24-hTNFA-IRES-hIL2, igrelimogene litadenorepvec) has demonstrated favorable safety profiles in phase 1 clinical trials in patients...” PMID 41566775 ↗ Jan 2026 |
| Known as | Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) | “Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)” NCT05271318 ↗1“Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)” NCT06125197 ↗ |
| Known as | Igrelimogen litadenorepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314682 ↗ |
| Known as | TILT-123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06961786 ↗ |
| Route | Intravenous | “Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors” PMID 39506856 ↗ Nov 2024 |